We are live on ! Find out more
PAI

ProQuest Associates IV Portfolio holdings

AUM $53M
1-Year Est. Return 3.35%
This Fund
S&P 500
This Quarter Est. Return
+24.41%
1 Year Est. Return
+3.35%
3 Year Est. Return
+113.14%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$78.2M
AUM Growth
-$254M
Cap. Flow
-$260M
Cap. Flow %
-332.04%
Top 10 Hldgs %
100%
Holding
5
New
2
Increased
–
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
URGN icon
UroGen Pharma
URGN
+$25.2M
2
MRSN
Mersana Therapeutics
MRSN
+$13.2M

Top Sells

Rank Stock Value
1
EGRX
Eagle Pharmaceuticals, Inc.
EGRX
+$298M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
URGN icon
1
UroGen Pharma
URGN
$2.13B
$26.2M 33.51%
+1,451,329
New +$25.2M
IMDZ
2
DELISTED
Immune Design Corp.
IMDZ
$19.1M 24.47%
1,962,720
– –
AGRX
3
DELISTED
Agile Therapeutics
AGRX
$19M 24.27%
2,531
– –
MRSN
4
DELISTED
Mersana Therapeutics
MRSN
$13.4M 17.07%
+38,228
New +$13.2M
EGRX
5
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$535K 0.68%
6,782
-3,645,502
-100% -$298M

Similar funds

CCP
Centaur Capital Partners Southlake, Texas $54.1M AUM 12.4% 1-Year Est. Return
CLA
Cranberry Lake Advisors Houston, Texas $50.6M AUM 5.12% 1-Year Est. Return
HC
Hampstead Capital London, United Kingdom $55.8M AUM 2.76% 1-Year Est. Return
SF
Schooner Foundation Boston, Massachusetts $49.6M AUM 9.4% 1-Year Est. Return
DIV
DCM International V Menlo Park, California $47.8M AUM 19.52% 1-Year Est. Return
MGPI
Maveron General Partner III Seattle, Washington $46.7M AUM 35.29% 1-Year Est. Return
MCAI
Meritech Capital Associates III Palo Alto, California $45.8M AUM 24.9% 1-Year Est. Return
P
PhaseCapital New York $45.2M AUM 8.85% 1-Year Est. Return

ProQuest Associates IV's Q2 2017 Portfolio in Review

As of Q2 2017, ProQuest Associates IV held 5 positions worth $78.2M, down 76% from $333M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

ProQuest Associates IV withdrew a net $260M in Q2 2017, reducing 1 holding. Its largest reduction was Eagle Pharmaceuticals, Inc., cutting an estimated $298M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, ProQuest Associates IV opened a new position in UroGen Pharma worth $26.2M.

  • ProQuest Associates IV's largest Q2 2017 buy was UroGen Pharma: 1,451,329 shares worth $26.2M.
  • ProQuest Associates IV's biggest Q2 2017 reduction was Eagle Pharmaceuticals, Inc., cutting an estimated $298M.
  • ProQuest Associates IV's ten largest holdings make up 100% of its $78.2M portfolio in Q2 2017.
  • ProQuest Associates IV opened 2 new positions and closed 0 in Q2 2017.
  • ProQuest Associates IV's portfolio value fell 76% quarter-over-quarter to $78.2M.

Based on ProQuest Associates IV's 13F filing for Q2 2017, filed 14 Aug 2017.